|
| 38062732 | Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. | Thyroid | 2024 |
| 36464853 | Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24â¿¿mg/day. | Cancer Medicine | 2023 |
| 38009200 | Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. | | 2023 |
| 38096102 | Real-World Practice Patterns and Outcomes for RAI-Refractory Differentiated Thyroid Cancer. | | 2023 |
| 37870969 | Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer. | N Engl J Med | 2023 |
| 37769225 | Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors. | JCO Precis Oncol | 2023 |
| 36869986 | Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer. | | 2023 |
| 36608305 | A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. | | 2023 |
| 35201680 | Diagnosis and management of TRK fusion cancer. | Am J Manag Care | 2022 |
| 35969032 | LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancer. | Future Oncol | 2022 |
| 35950621 | Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). | Thyroid | 2022 |
| 35486879 | Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study. | Journal of Clinical Oncology | 2022 |
| 35672677 | Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. | BMC Cancer | 2022 |
| 36259380 | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. | Cancer | 2022 |
| 35536733 | Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. | Oncologist | 2022 |
| 35333737 | Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. | Eur J Endocrinol | 2022 |
| 35274388 | American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. | Head Neck | 2022 |
| 34664662 | A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. | Journal of Clinical Endocrinology and Metabolism | 2022 |
| 35201681 | Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. | Am J Manag Care | 2022 |
| 33961488 | Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. | J Clin Oncol | 2021 |
| 34237250 | Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2021 |
| 34118198 | Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. | Lancet Diabetes Endocrinol | 2021 |
| 31540966 | Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. | Molecular Cancer Therapeutics | 2020 |
| 32167863 | Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. | Journal of Clinical Oncology | 2020 |
| 32846061 | Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers. | N Engl J Med | 2020 |
| 32614439 | Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation: Is It Time for a Paradigm Shift? | JAMA Otolaryngology - Head and Neck Surgery | 2020 |
| 32557577 | Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. | Cancer | 2020 |
| 30832606 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. | BMC Cancer | 2019 |
| 31558473 | Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial. | Clinical Cancer Research | 2019 |
| 31860408 | Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. | Thyroid | 2019 |
| 30471649 | Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. | European Journal of Cancer | 2019 |
| 30624546 | Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. | Ann Oncol | 2019 |
| 30922731 | Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. | Lancet Oncology, The | 2019 |
| 30920122 | Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer. | Clinical and Translational Science | 2019 |
| 29466156 | Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. | N Engl J Med | 2018 |
| 29704768 | Management of treatment-related toxicities in advanced medullary thyroid cancer. | Cancer Treat Rev | 2018 |
| 29657135 | Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers. | Cancer Discov | 2018 |
| 29656442 | Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). | Cancer | 2018 |
| 28270435 | Timing of multikinase inhibitor initiation in differentiated thyroid cancer. | | 2017 |
| 28911726 | Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. | | 2017 |
| 28613956 | Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. | Journal of Clinical Oncology | 2017 |
| 29045520 | Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. | Ann Oncol | 2017 |
| 30018844 | The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers. | | 2017 |
| 27819236 | Vemurafenib for BRAF-positive metastatic papillary thyroid cancer - Authors' response. | Lancet Oncology, The | 2016 |
| 27168343 | Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion. | Clinical Advances in Hematology and Oncology | 2016 |
| 27168342 | Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer. | Clinical Advances in Hematology and Oncology | 2016 |
| 26994002 | pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. | Hormones and Cancer | 2016 |
| 27460442 | Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. | Lancet Oncol | 2016 |
| 26662608 | STK11 Mutation Identified in Thyroid Carcinoma. | Endocrine Pathology | 2016 |
| 27525386 | Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. | Cancer | 2016 |